We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-11.53%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$361M
AUM Growth
+$175M
Cap. Flow
-$29.7M
Cap. Flow %
-8.24%
Top 10 Hldgs %
90.77%
Holding
111
New
18
Increased
19
Reduced
27
Closed
38

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$5.25M
2
TRAW icon
Traws Pharma
TRAW
+$3.96M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$1.9M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$1.16M
5
TOPS icon
TOP Ships
TOPS
+$1.13M

Top Sells

Rank Stock Value
1
TEUM
Pareteum Corporation
TEUM
+$2.9M
2
RDGT
Ridgetech Inc
RDGT
+$1.59M
3
CRMD icon
CorMedix
CRMD
+$1.59M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$1.28M
5
ATNM icon
Actinium Pharmaceuticals
ATNM
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 5.35%
2 Industrials 0.18%
3 Technology 0.07%
4 Consumer Discretionary 0.01%
5 Materials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLUR icon
26
PUT
Pluri
PLUR
$18.1M
$708K 0.2%
225
+203
+923% +$5.82K
AVEO
27
PUT
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$673K 0.19%
1,085
+495
+84% +$3.64K
TOPS icon
28
TOP Ships
TOPS
$4.11M
$639K 0.18%
133
+99
+291% +$1.13M
BNTC icon
29
Benitec Biopharma
BNTC
$408M
$603K 0.17%
4,639
-716
-13% -$108K
AUPH icon
30
CALL
Aurinia Pharmaceuticals
AUPH
$1.92B
$590K 0.16%
291
-1,386
-83% -$12.8K
PHAS
31
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$576K 0.16%
94,351
-30,437
-24% -$125K
AMRN
32
Amarin Corp
AMRN
$293M
$575K 0.16%
1,341
-209
-13% -$79.4K
PSTV icon
33
Plus Therapeutics
PSTV
$25.9M
$562K 0.16%
624
+321
+106% +$294K
NMTR
34
DELISTED
9 Meters Biopharma
NMTR
$525K 0.15%
47,079
-15,362
-25% -$256K
CRVO icon
35
CervoMed
CRVO
$23.7M
$500K 0.14%
14,473
+8,235
+132% +$503K
GHSI
36
DELISTED
Guardion Health Sciences, Inc. Common Stock
GHSI
$439K 0.12%
+6,646
New +$635K
PULM icon
37
Pulmatrix
PULM
$6.14M
$384K 0.11%
22,337
-30,597
-58% -$485K
XBIO icon
38
Xenetic Biosciences
XBIO
$5.73M
$382K 0.11%
26,550
-13,905
-34% -$177K
PALI icon
39
Palisade Bio
PALI
$351M
$378K 0.1%
85
+39
+85% +$195K
TOVX icon
40
Theriva Biologics
TOVX
$9.8M
$348K 0.1%
2,749
-593
-18% -$63.1K
XBIOW
41
DELISTED
Xenetic Biosciences, Inc. Warrants
XBIOW
$297K 0.08%
216,789
-50,000
-19% -$65.7K
AIM
42
AIM ImmunoTech
AIM
$6.54M
$288K 0.08%
5,293
+3,439
+185% +$173K
CYTO
43
DELISTED
Altamira Therapeutics Ltd
CYTO
$278K 0.08%
430
+11
+3% +$7.46K
NURO
44
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$275K 0.08%
7,985
-3,693
-32% -$107K
LFWD icon
45
ReWalk Robotics
LFWD
$19.6M
$273K 0.08%
1,503
+134
+10% +$29.1K
NSPR icon
46
InspireMD
NSPR
$32.1M
$270K 0.07%
16,667
-4,238
-20% -$67.1K
OTLK icon
47
Outlook Therapeutics
OTLK
$169M
$229K 0.06%
+19,447
New +$453K
AVEO
48
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$225K 0.06%
+363
New +$2.67K
PLUR icon
49
Pluri
PLUR
$18.1M
$222K 0.06%
7,055
+2,406
+52% +$69K
ABEO icon
50
Abeona Therapeutics
ABEO
$343M
$197K 0.05%
+2,414
New +$170K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sabby Management held 111 positions worth $361M, up 94% from $186M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Sabby Management withdrew a net $29.7M in Q4 2019, closing 38 positions and reducing 27 holdings. Its most notable exit was Pareteum Corporation, an estimated $2.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 5.4% of assets, down from 15% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sabby Management opened a new position in SPDR Gold Trust worth $5.37M.

  • Sabby Management's largest Q4 2019 buy was SPDR Gold Trust: 37,550 shares worth $5.37M.
  • Sabby Management added most to Traws Pharma in Q4 2019, an estimated $3.96M increase.
  • Sabby Management's biggest Q4 2019 reduction was Actinium Pharmaceuticals, cutting an estimated $1.27M.
  • Sabby Management fully exited Pareteum Corporation in Q4 2019, selling an estimated $2.9M.
  • Sabby Management's ten largest holdings make up 91% of its $361M portfolio in Q4 2019.
  • Sabby Management opened 18 new positions and closed 38 in Q4 2019.
  • Sabby Management's portfolio value rose 94% quarter-over-quarter to $361M.

Based on Sabby Management's 13F filing for Q4 2019, filed 14 Feb 2020.